CGEN (Compugen) Moat Score: 4/10 (As of Jun. 28, 2026)


CGEN Compugen Ltd CGEN
60 GF Score
Price $2.10
GF Value $5.39
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Compugen Moat Score?

Compugen CGEN +2.45% 60 Moat Score is 4 as of Jun. 28, 2026. GuruFocus rates CGEN with a GF Score™ of 60/100 and a GF Value™ of $5.39 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,402 Biotechnology companies, Compugen ranks better than 88.8% on this metric.

Compugen has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Compugen has Narrow Moat: Compugen Ltd has a discernible but modest moat with a focus on innovative drug discovery and some valuable intellectual property. However, it operates in a competitive biotech sector with limited market share and brand strength.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Compugen might have Narrow Moat - Discernible but modest moat.

Compugen  (NAS:CGEN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Compugen Moat Score Related Terms

CGEN vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Compugen's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Compugen Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Compugen's Moat Score distribution charts can be found below:

* The bar in red indicates where Compugen's Moat Score falls into.


CGEN
60GF Score
Compugen Ltd CGEN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Compugen (CGEN) has a Moat Score of 4 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Compugen ranks #157 out of 1402 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Compugen's Moat Score too high?
Compugen's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Compugen's value of 4 is 100% above this industry median. Based on the distribution chart, Compugen ranks #157 out of 1402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Compugen has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Compugen's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Compugen ranks #157 out of 1402 companies for Moat Score. This places Compugen in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Compugen's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compugen's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compugen's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compugen stock overvalued right now?
Based on GuruFocus' analysis, Compugen (CGEN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.39, compared to a current price of $2.10 — trading 61% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Compugen's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Compugen (CGEN), the current Moat Score is 4 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Compugen (CGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Compugen stock appears to be undervalued. The current stock price of $2.10 is trading 61% below its estimated GF Value™ of $5.39. GuruFocus considers Compugen to be Possible Value Trap.

Key valuation signals for CGEN:

  • Moat Score: 4
  • GF Value™: $5.39 vs. price of $2.10 (61% below fair value)
  • GF Score™: 60/100 with 4 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1402)

No single metric tells the full story. See the CGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Compugen Business Description

Other Exchanges CGEN:Israel
Address 26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
60GF Score

Get the complete analysis for CGEN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price
$5.39
GF Value